TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22114787

Group type: EXPERIMENTAL
Intervention: Vitamin D3‐fortified yogurt drink (FYD; containing 170 mg calcium and 500 IU/250 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plain yogurt drink (PYD; containing 170 mg calcium and no vitamin D/250 mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin D3‐fortified yogurt drink (FYD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plain yogurt drink (PYD)
Number of subjects: 100
Study: 20225476

Group type: EXPERIMENTAL
Intervention: 1.10 mm diameter cast Ni-Cr alloy post-core
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1.50 mm diameter cast Ni-Cr alloy post-core
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1.70 mm diameter cast Ni-Cr alloy post-core
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2.00 mm diameter cast Ni-Cr alloy post-core
Number of subjects: 32
Study: 16464371

Group type: EXPERIMENTAL
Intervention: 'yi qi tiao xue, fu ben pei yuan' acupuncture method (supplementing vital force‐matter and regulating blood, supporting the root and fostering the source)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment (medication and traditional acupuncture treatment)
Number of subjects: 60
Study: 15175213

Group type: COMPARATOR
Intervention: Plain lubricant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine gel
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Younger women (aged 18-59)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preprocedural pain
Number of subjects: 100
Study: 11131819

Group type: EXPERIMENTAL
Intervention: Verbal evaluation of moves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-verbal evaluation of moves (key press)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation processes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-evaluated solutions
Number of subjects: 0
Study: 9068022

Group type: EXPERIMENTAL
Intervention: 40 mmol/L lactate dialysate
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 38 mmol/L bicarbonate fluid
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 25 mmol/L bicarbonate and 15 mmol/L lactate dialysate
Number of subjects: 47
Study: 7814812

Group type: EXPERIMENTAL
Intervention: Alpha interferon treatment
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Low dose alpha interferon (≤ 200 MU/m2)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Medium/high dose alpha interferon (≥ 200 MU/m2)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 751
Study: 2690545

Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin
Number of subjects: 145

Group type: COMPARATOR
Intervention: 12 g cholestyramine
Number of subjects: 145
Study: 1099036

Group type: EXPERIMENTAL
Intervention: 30% sodium thiosulfate application
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 30% sodium thiosulfate application plus ultraviolet light
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 30% sodium thiosulfate application, ultraviolet light, and meladinine tablets (amoidin 0.01 g and amidin 0.005 g)
Number of subjects: 134
Study: 31585966

Group type: EXPERIMENTAL
Intervention: New revised manual and a 1-day workshop delivered by voluntary sector service providers
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 64
Study: 26829647

Group type: EXPERIMENTAL
Intervention: 30 or 60 mg gevokizumab every 4 weeks intravenously or subcutaneously
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gevokizumab
Number of subjects: 21
Study: 24164634

Group type: EXPERIMENTAL
Intervention: Full vision
Number of subjects: 28

Group type: COMPARATOR
Intervention: Target only vision
Number of subjects: 28
Study: 22406015

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 40 m s(‐2) (30 Hz High, 2.5 mm)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with hand straps
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with soft mat
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline (no WBV)
Number of subjects: 14
Study: 20713437

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation therapy (CST)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 18589556

Group type: EXPERIMENTAL
Intervention: Epoetin zeta (10,000 IU, subcutaneous injection)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Epoetin alfa (10,000 IU, subcutaneous injection)
Number of subjects: 48
Study: 16583597

Group type: EXPERIMENTAL
Intervention: Whitening lamp and peroxide gel (20% hydrogen peroxide)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No light treatment with peroxide gel (20% hydrogen peroxide)
Number of subjects: 50
Study: 11854731

Group type: EXPERIMENTAL
Intervention: Autogenous saphenous vein (ASV)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Synthetic patches
Number of subjects: 195
Study: 10235191

Group type: EXPERIMENTAL
Intervention: Low fat meal (10% fat, 14% proteins, 76% carbohydrates)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High fat meal (50% fat, 18% proteins, 32% carbohydrates)
Number of subjects: 12
Study: 7633717

Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (3 mg/m2 body-surface area)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin
Number of subjects: 10
Study: 2653057

Group type: EXPERIMENTAL
Intervention: Carbamazepine, 800 mg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oxazepam, 120 mg/day
Number of subjects: 66
Study: 71396

Group type: EXPERIMENTAL
Intervention: Live attenuated measles vaccine (Schwarz strain)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Unvaccinated group
Number of subjects: 5000
Study: 30201160

Group type: EXPERIMENTAL
Intervention: Speech Recognition (SR) intervention
Number of subjects: 4510
Study: 28673375

Group type: EXPERIMENTAL
Intervention: Dietary inflammatory index (DII) score
Number of subjects: 1304

Group type: EXPERIMENTAL
Intervention: High DII scores
Number of subjects: 1304
Study: 26158868

Group type: COMPARATOR
Intervention: Standard-size ETT (8.0 mm for men and 7.5 mm for women)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Small ETT (7.0 mm for men and 6.5 mm for women)
Number of subjects: 49
Study: 24085380

Group type: EXPERIMENTAL
Intervention: Percutaneous compression plate (PCCP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Proximal femoral nail anti-rotation (PFNA)
Number of subjects: 90
Study: 21897262

Group type: EXPERIMENTAL
Intervention: Sternotomy (group TLV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thoracotomy (group OLV)
Number of subjects: 0
Study: 19117865

Group type: EXPERIMENTAL
Intervention: Lucinactant 90 mg/kg
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Lucinactant 175 mg/kg
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (sham air)
Number of subjects: 136
Study: 16434916

Group type: EXPERIMENTAL
Intervention: Mail survey
Number of subjects: 9126

Group type: COMPARATOR
Intervention: Web survey
Number of subjects: 9126

Group type: COMPARATOR
Intervention: IVR survey
Number of subjects: 9126

Group type: EXPERIMENTAL
Intervention: Mail and Web comparison
Number of subjects: 9126

Group type: COMPARATOR
Intervention: IVR comparison
Number of subjects: 9126

Group type: COMPARATOR
Intervention: Cost comparison
Number of subjects: 9126
Study: 15017527

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ARB and ACE inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan and Irbesartan (specific ARBs)
Number of subjects: 0
Study: 11701102

Group type: EXPERIMENTAL
Intervention: Formal tests of interaction
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Subgroup-specific tests
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Formal interaction tests
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Subgroup-specific analyses
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Inflation factor for sample size
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Subgroup analyses
Number of subjects: 200
Study: 9233053

Group type: EXPERIMENTAL
Intervention: Sumatriptan (SU) 6 mg s.c.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sumatriptan (SU) plus GHRH
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL) plus GHRH
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sumatriptan (SU)
Number of subjects: 14
Study: 8365194

Group type: EXPERIMENTAL
Intervention: Statistical models (Altham's and beta-binomial) for analyzing graft occlusion rates
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Mixed model or Markov-like susceptibility model
Number of subjects: 349
Study: 2877129

Group type: EXPERIMENTAL
Intervention: Synvinolin (MK-733) 2.5 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Synvinolin (MK-733) 80 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Synvinolin (MK-733) (doses ranging from 2.5 mg to 80 mg per day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 29103133

Group type: EXPERIMENTAL
Intervention: Growtropin®‐II (recombinant human GH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 27786541

Group type: EXPERIMENTAL
Intervention: 5-min cold-water immersion at 8 °C
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10-min cold-water immersion at 8 °C
Number of subjects: 15

Group type: COMPARATOR
Intervention: Passive rest
Number of subjects: 15
Study: 25472660

Group type: EXPERIMENTAL
Intervention: Radioembolisation (RE) with yttrium-90 microspheres (SIR-Spheres™)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 440
Study: 22831889

Group type: EXPERIMENTAL
Intervention: Remifentanil during cardiac surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Not receiving remifentanil
Number of subjects: 120
Study: 20059676

Group type: EXPERIMENTAL
Intervention: Patient feedback training programme in addition to regular communication skills training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Regular communication skills training
Number of subjects: 53
Study: 18226766

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Furosemide (intravenous diuretics)
Number of subjects: 19
Study: 15629205

Group type: EXPERIMENTAL
Intervention: Huntington's disease patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 22
Study: 12589153

Group type: EXPERIMENTAL
Intervention: Clodronate (1600 mg/day in two divided doses)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10779192

Group type: EXPERIMENTAL
Intervention: Negative pressure (vacuum suction) at 40 mmHg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Negative pressure (vacuum suction) at 50 mmHg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Negative pressure (vacuum suction) at 60 mmHg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Negative pressure (vacuum suction) at 70 mmHg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no vacuum)
Number of subjects: 24
Study: 8668962

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 1 g of IgG in 10 ml saline
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intra-articular injection of 10 ml physiological saline
Number of subjects: 11
Study: 1844697

Group type: EXPERIMENTAL
Intervention: Two formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence interval approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothetical data set from a two‐by‐two crossover bioequivalence study
Number of subjects: 0
Study: 6303104

Group type: EXPERIMENTAL
Intervention: Low energy density diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: High energy density diet
Number of subjects: 20
Study: 30629585

Group type: EXPERIMENTAL
Intervention: Blood pressure checks once a year for chronic disease patients without a diagnosis of hypertension
Number of subjects: 8947

Group type: EXPERIMENTAL
Intervention: Current practice of blood pressure checks every 7 weeks for individuals with hypertension
Number of subjects: 8947

Group type: COMPARATOR
Intervention: Routine blood pressure checks at every visit
Number of subjects: 8947
Study: 30106172

Group type: EXPERIMENTAL
Intervention: Galcanezumab (120 mg subcutaneous injection)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 25469889

Group type: EXPERIMENTAL
Intervention: Tuning in to Kids
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Positive Parenting Program
Number of subjects: 320

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 320
Study: 24202432

Group type: EXPERIMENTAL
Intervention: Controlled-ventilation technique
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-protocolized anesthesia
Number of subjects: 42
Study: 23176889

Group type: EXPERIMENTAL
Intervention: Subcutaneous allergy immunotherapy
Number of subjects: 18
Study: 19254374

Group type: EXPERIMENTAL
Intervention: Time constraints (median agreement of 3, IQR 2-5)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Difficulties including identified eligible patients (median agreement of 5, IQR 3-6)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Trial design barriers, lack of access to treatment, individual barriers of recruiting physicians, insufficient training of recruiting physicians
Number of subjects: 35
Study: 17966072

Group type: EXPERIMENTAL
Intervention: Aluminum (Amphojel plus citrate) administered orally for 3 days followed by a 3-week washout, then matched placebo for 3 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered for 3 days after aluminum treatment.
Number of subjects: 0
Study: 15564357

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 73
Study: 11556665

Group type: EXPERIMENTAL
Intervention: Ultrasound time-of-flight (ToF) posturography measurements during balance assessment on solid and soft surfaces.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vestibular therapy post-therapy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound ToF method for tracking sway.
Number of subjects: 0
Study: 10074720

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous immunoglobulin (IVIG) therapy, 750-1000 mg/kg for infants <1000 g, 500-750 mg/kg for infants 1001-1500 g, administered every 2 weeks until 1800 g or discharge
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group received saline infusion, administered every 2 weeks until 1800 g or discharge
Number of subjects: 61
Study: 7839076

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone pulse therapy (100 mg in 250 ml 5% dextrose infused over 1 h, repeated every month for 6 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone pulse therapy
Number of subjects: 35
Study: 3060542

Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream applied five times daily for 5 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 28854833

Group type: EXPERIMENTAL
Intervention: Sacha inchi flour (30g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Soybean flour (30g)
Number of subjects: 30
Study: 27478849

Group type: EXPERIMENTAL
Intervention: Topical pirfenidone plus conventional treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 24
Study: 24599010

Group type: EXPERIMENTAL
Intervention: High-dose angiotensin II receptor blocker (ARB)
Number of subjects: 1164

Group type: COMPARATOR
Intervention: ARB plus calcium channel blocker (CCB)
Number of subjects: 1164
Study: 22893165

Group type: EXPERIMENTAL
Intervention: Partner violence screen plus a list of local partner violence resources (n = 801)
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Partner violence resource list only (n = 772)
Number of subjects: 2708

Group type: COMPARATOR
Intervention: No-screen, no-partner violence list control group (n = 791)
Number of subjects: 2708
Study: 20674497

Group type: EXPERIMENTAL
Intervention: Metabolic therapy (coenzyme Q(10), magnesium orotate, lipoic acid, omega‐3 fatty acids and selenium)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 17945470

Group type: EXPERIMENTAL
Intervention: Depakine-chrono (40 patients) for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (40 patients) for 6 weeks
Number of subjects: 80
Study: 15748102

Group type: EXPERIMENTAL
Intervention: Alternate Rapid Maxillary Expansions and Constrictions (Alt‐RAMEC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 26
Study: 12452233

Group type: EXPERIMENTAL
Intervention: 5 g of EMLA cream
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 ml of 1% lidocaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 ml of 2% lidocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90
Study: 10592355

Group type: EXPERIMENTAL
Intervention: Twice-weekly hemodialysis
Number of subjects: 15067

Group type: COMPARATOR
Intervention: Thrice-weekly hemodialysis
Number of subjects: 15067
Study: 7577286

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.2 mg kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tubocurarine 0.5 mg kg‐1
Number of subjects: 75

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 75

Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 75
Study: 1962902

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (FR‐860) at 75 U/kg/day in group I (n = 27)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (FR‐860) at 150 U/kg/day in group II (n = 29)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 6273027

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (mean dose 0.5 microgram daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: D3 (dose 100 microgram daily)
Number of subjects: 17
Study: 29942978

Group type: EXPERIMENTAL
Intervention: Cardiac shock wave therapy (CSWT)
Number of subjects: 50
Study: 27798812

Group type: EXPERIMENTAL
Intervention: Nordic walking training (NWT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treadmill training (TT)
Number of subjects: 20
Study: 25599449

Group type: EXPERIMENTAL
Intervention: Testosterone replacement (5 g of transdermal gel daily for 14 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (14 weeks)
Number of subjects: 84
Study: 24073230

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire modes
Number of subjects: 1483

Group type: COMPARATOR
Intervention: Interviewer-administered questionnaire mode
Number of subjects: 1483

Group type: EXPERIMENTAL
Intervention: Self-administered modes (when completed twice)
Number of subjects: 1483
Study: 21416219

Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135 mg added to moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg) for 52 weeks
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fenofibric acid with moderate-dose statin
Number of subjects: 92
Study: 19531728

Group type: EXPERIMENTAL
Intervention: Regular coffee (caffeinated)
Number of subjects: 103

Group type: COMPARATOR
Intervention: De-caffeinated coffee
Number of subjects: 103
Study: 15641936

Group type: EXPERIMENTAL
Intervention: Low-T3 positive HD-pts (decreased fT3 and increased rT3)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-T3 positive HD-pts
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: QRSd
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RMS40
Number of subjects: 52
Study: 12747648

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (GDx-NFA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Confocal scanning laser ophthalmoscopy (HRT-II)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: GDx parameters
Number of subjects: 53
Study: 10567757

Group type: EXPERIMENTAL
Intervention: F-scan pressure sensitive insole system
Number of subjects: 0
Study: 8916520

Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation program including a meeting with the nurse-case manager, videotape, workbook, relaxation audiotape, nicotine replacement therapy, and nurse-initiated phone contacts after discharge
Number of subjects: 660

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 660
Study: 2011802

Group type: EXPERIMENTAL
Intervention: High-intensity intervention
Number of subjects: 4087

Group type: EXPERIMENTAL
Intervention: Low-intensity intervention
Number of subjects: 4087

Group type: COMPARATOR
Intervention: Control area
Number of subjects: 4087
Study: 7114339

Group type: EXPERIMENTAL
Intervention: Group 1 (family involvement and home visits)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Group 2 (home visits from nurses and pharmacists)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 218
Study: 31067282

Group type: EXPERIMENTAL
Intervention: 12 video clips related to maternal and neonatal health information
Number of subjects: 155
Study: 28859485

Group type: EXPERIMENTAL
Intervention: Cyberwand
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lithoclast Select
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: StoneBreaker
Number of subjects: 201

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 201
Study: 26363417

Group type: EXPERIMENTAL
Intervention: lipid emulsion alone (LE, Fabuless™ 4.2g lipid, 0.2MJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: lipid control alone (LC, 4.2g lipid, 0.2 MJ)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LE+yoghurt (1.2 MJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: LC+yoghurt (1.2MJ)
Number of subjects: 18
Study: 23351426

Group type: EXPERIMENTAL
Intervention: Adverse information on the risks of the combined oral pill
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Promotional material on the vaginal ring and transdermal patch
Number of subjects: 527

Group type: COMPARATOR
Intervention: Basic information on contraceptive products
Number of subjects: 527